Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results
Total Revenue of $7.6 Million for 1Q 2021; TAZVERIK® Net Product Revenues of $6.2 Million
Ongoing TAZVERIK Clinical Trials in both Follicular Lymphoma and Prostate Cancer Demonstrate Encouraging Preliminary Safety and Activity Data
Investigational New Drug (IND) Submission for Novel SETD2 Inhibitor Program Planned for Mid-2021
Conference Call Today,